(Il Sole 24 Ore Radiocor Plus) – Milan, May 20 – The Roche pharmaceutical group expects to return 51 million euros to the NHS (National Health Service) for the period 2012-2015 thanks to the commercial agreements on drugs with the Aifa agency. Thus a note from the Swiss company.
"Roche has always been committed to guaranteeing sustainability by re-injecting resources into the Italian health system and to seeking solutions that allow for the release of others so that they can be reinvested for the benefit of the patient", he stated Maurice de Cicco, CEO of Roche SpA, who adds: "for this reason we have been courageous pioneers in activating negotiating agreements for innovative drugs with AIFA, with the aim of combining appropriate access to the country's sustainability".
The group cites in particular as an example of excellence the anticancer drug Avastin, which is also used to treat some eye diseases, for which a 'multi-indication' agreement was signed with Aifa which links the reimbursement of the drug to the different value of treatment in different indications. From 2007 to 2012, thanks to the negotiated agreements, Avastin returned 47.5 million and it is estimated that it will pay another 42 to the NHS for 2012-2015.
Finally, Roche recalls that, in addition to the negotiating agreements with Aifa, following the introduction of the hospital payback (the mechanism that requires pharmaceutical companies engaged in innovation since 2013 to take charge of the 50% of the breach of the hospital pharmaceutical expenditure ceiling) "it contributes to the shelf for about double its market share, making it by far the company that contributes the most to the shelf with about a further 150 million in total, of which 85 million for 2014 spending alone”.
com-pal-
(RADIOCOR) 20-05-16 13:58:15 (0319) 5 NNNN
